Discover How Research Agencies Can Assist Manufacturers With A Premarket Tobacco Product Application

1. Discover How Research Agencies Can Assist Manufacturers With A Premarket Tobacco Product Application To Comply With Government Legislation A Premarket Tobacco Product Application (PMTA) can be submitted by any product manufacturer of a new tobacco product, who seeks an FDA marketing order. The purpose is to provide regulatory bodies such as the Food and Drug Administration with scientific proof that the product is appropriate, in order to comply with the public health protection bill. However, the process of premarket tobacco product application can be very complicated, and for most manufacturers, it remains a challenging task, especially when all they want to do is introduce their new product to the market and see if flying off the shelves. For this reason, manufacturers of tobacco products sometimes enlist the services of reputable, internationally recognised research agencies to assist them in the application process. Research agencies and leaders in the field of behavioural science in tobacco harm reduction and usually work in close relation with tobacco companies like British American Tobacco (BAT) to ensure approval of their Premarket Tobacco Product Applications. Through extensive research, these companies are able to not only obtain relevant to ensure that quality and control is brought to the tobacco industry but also advocate harm reduction of tobacco products. For the general public, especially users of tobacco products, it can be easy to mistakenly think that regulatory requirements are just a means to make money, but no amount of money can be placed on the life of a human being and the fact remains that tobacco products, including tobacco cigarettes, e-cigarettes and vapes, are detrimental to one’s health. The principal aim of PMTA is to encourage tobacco manufacturers to comply with regulation and keep their products, as well as consumers safe. Consumers need to be protected and in countries like the UK, legislation (the Tobacco Regulation Act of 2003) prohibits the sale of single cigarettes or small packs of cigarettes, tobacco for oral use and tobacco products via vending machines. Tobacco products can also not be sold to any person under the age of 18 years. Under the same omnibus law as mentioned above, the advertising of tobacco cigarettes, sponsorship and promotion thereof, and smoking in public places is also prohibited. Consumers sometimes wonder why such legislation even exists, but based on extensive research and scientific evidence, these rules have been created to create a healthier future for British citizens and to protect the public against tobacco harm. Despite public health campaigns and various forms of legislation, smoking of tobacco products remains the top avoidable cause of worldwide deaths, and currently, it is costing the world

2. economy millions every year in healthcare expenses and loss of productivity. The burden of tobacco-related costs also puts heavier pressure on those who can least afford it, yet the consumption of tobacco products continues to rise every year, including the sales of c- cigarettes and vaping devices. This can be largely attributed to the aggressive marketing by tobacco companies. The use of and exposure to tobacco is a public health issue that should in fact receive more attention (this remains a debatable topic for many) and had it not been for legislation and the valuable, weight-bearing substance research by leading research agencies, perhaps half of the world’s population would have been wiped out from lung and heart diseases by this time. Tobacco giants like BAT are some of the largest cigarette manufacturers in the world and yet they work closely with research agencies to promote and even encourage tobacco harm reduction and good health in general. Perhaps now you will better understand the words of warnings like ‘smoking is dangerous’ and ‘Smoking kills’, which are often printed on the packaging of tobacco products. About us: CSUR is a Global Leader on Behavioural Science in Tobacco Harm Reduction, operating from their base at the Centre for Substance Use Research Ltd in Glasgow. CSUR opened in 1994 linked initially to the University of Glasgow, and in 2011 CSUR became a wholly independent research centre focussing on a wider range of substance use issues and developing a large programme of behaviourally focussed regulatory science research assessing the contribution of ENDS in reducing tobacco-related health harm. Our team comprises post- doctoral researchers in behavioural science, experts in marketing, cybersecurity, and media. Our focus is on furthering the goals of tobacco-related harm reduction and assessing the public health impact of Electronic Nicotine Delivery Systems and our goal is to ensure that those working within these industries have access to high-quality behavioural research that can further their owns goals of reducing the harms associated with the use of combustible tobacco products. Find out more by visiting our website at https://www.csures.com.